REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $564.95 million. The enterprise value is $531.05 million.
Important Dates
The next estimated earnings date is Thursday, March 12, 2026, after market close.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 50.62 million shares outstanding. The number of shares has increased by 7.46% in one year.
| Current Share Class | 50.62M |
| Shares Outstanding | 50.62M |
| Shares Change (YoY) | +7.46% |
| Shares Change (QoQ) | +0.40% |
| Owned by Insiders (%) | 8.35% |
| Owned by Institutions (%) | 73.23% |
| Float | 41.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.55 |
| Forward PS | 2.45 |
| PB Ratio | 3.50 |
| P/TBV Ratio | 3.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.66, with a Debt / Equity ratio of 1.66.
| Current Ratio | 2.66 |
| Quick Ratio | 2.55 |
| Debt / Equity | 1.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.68 |
Financial Efficiency
Return on equity (ROE) is -76.88% and return on invested capital (ROIC) is -97.61%.
| Return on Equity (ROE) | -76.88% |
| Return on Assets (ROA) | -18.54% |
| Return on Invested Capital (ROIC) | -97.61% |
| Return on Capital Employed (ROCE) | -38.67% |
| Weighted Average Cost of Capital (WACC) | 10.86% |
| Revenue Per Employee | $456,992 |
| Profits Per Employee | -$504,008 |
| Employee Count | 353 |
| Asset Turnover | 0.31 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +48.40% in the last 52 weeks. The beta is 1.07, so REGENXBIO's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | +48.40% |
| 50-Day Moving Average | 13.50 |
| 200-Day Moving Average | 10.50 |
| Relative Strength Index (RSI) | 36.53 |
| Average Volume (20 Days) | 1,053,304 |
Short Selling Information
The latest short interest is 5.12 million, so 10.12% of the outstanding shares have been sold short.
| Short Interest | 5.12M |
| Short Previous Month | 4.97M |
| Short % of Shares Out | 10.12% |
| Short % of Float | 12.29% |
| Short Ratio (days to cover) | 6.85 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $161.32 million and -$177.92 million in losses. Loss per share was -$3.46.
| Revenue | 161.32M |
| Gross Profit | -78.44M |
| Operating Income | -154.93M |
| Pretax Income | -177.92M |
| Net Income | -177.92M |
| EBITDA | -139.16M |
| EBIT | -154.93M |
| Loss Per Share | -$3.46 |
Full Income StatementBalance Sheet
The company has $274.21 million in cash and $268.14 million in debt, with a net cash position of $33.90 million or $0.67 per share.
| Cash & Cash Equivalents | 274.21M |
| Total Debt | 268.14M |
| Net Cash | 33.90M |
| Net Cash Per Share | $0.67 |
| Equity (Book Value) | 161.45M |
| Book Value Per Share | 3.19 |
| Working Capital | 207.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$103.30 million and capital expenditures -$2.99 million, giving a free cash flow of -$106.28 million.
| Operating Cash Flow | -103.30M |
| Capital Expenditures | -2.99M |
| Free Cash Flow | -106.28M |
| FCF Per Share | -$2.10 |
Full Cash Flow StatementMargins
Gross margin is -48.62%, with operating and profit margins of -96.04% and -110.29%.
| Gross Margin | -48.62% |
| Operating Margin | -96.04% |
| Pretax Margin | -110.29% |
| Profit Margin | -110.29% |
| EBITDA Margin | -86.27% |
| EBIT Margin | -96.04% |
| FCF Margin | n/a |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.46% |
| Shareholder Yield | -7.46% |
| Earnings Yield | -31.49% |
| FCF Yield | -18.81% |
Analyst Forecast
The average price target for REGENXBIO is $30.38, which is 172.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.38 |
| Price Target Difference | 172.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 48.27% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -2.31 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.31 |
| Piotroski F-Score | 3 |
